Living with Parkinson’s means managing symptoms that change day to day. Finding the right medication balance is hard for many families. A new look at patient data suggests a specific test might help doctors choose better treatments for their patients more effectively.
Researchers tracked 223 people with Parkinson’s disease from a large initiative. Those with alpha-synuclein seeds in their spinal fluid responded better to levodopa over time. Their motor symptoms also progressed more slowly compared to those without the seeds.
The test measured brain changes linked to dopamine loss. Patients without the seeds showed faster decline in these areas. Researchers used an observational study design, so this shows a link, not proof that the test causes the difference. Patients with the seeds had fewer motor complications at the start, but progression remained similar later.
This finding helps explain why Parkinson’s looks different for everyone. It may guide future treatment choices for doctors. Confirming these results requires broader groups to validate the data further before wide adoption in clinics. This test status captures clinically relevant heterogeneity that may inform patient stratification and decision-making.